Published in Adv Anat Pathol on July 01, 1997
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci (2017) 0.76
Severe unexplained relative hypotension and bradycardia in the emergency department. Case Rep Emerg Med (2014) 0.75
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. Biomed Res Int (2014) 0.75
Protective effect of Korean Red Ginseng against FK506-induced damage in LLC-PK1 cells. J Ginseng Res (2016) 0.75
Posterior Reversible Encephalopathy Syndrome after Heart Transplantation: Diagnosis and Immunosuppressive Therapy. Tex Heart Inst J (2017) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med (1994) 4.22
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. Transplant Proc (1987) 2.84
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest (1994) 2.81
Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet (1992) 2.66
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation (1996) 2.24
The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation (1995) 2.13
Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest (1992) 2.13
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation (1989) 2.03
Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. Transplant Proc (1995) 1.70
Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69
Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int (1983) 1.65
Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc (1994) 1.59
Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation (1996) 1.57
Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis (1996) 1.55
Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg (1995) 1.54
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45
Toxicologic evaluation of FK 506. Transplant Proc (1990) 1.36
The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32
Pharmacokinetics of FK 506 in transplant patients. Transplant Proc (1991) 1.30
The effect of FK 506 and CyA on the Lewis rat renal ischemia model. Transplant Proc (1990) 1.28
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs (1993) 1.25
Segmental arterial mediolysis: a precursor to fibromuscular dysplasia? Mod Pathol (1995) 1.24
De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery (1985) 1.24
Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18
Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18
Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) (1981) 1.12
Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother (1976) 1.11
Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol (1995) 1.09
Cyclosporin A nephropathy: standardization of the evaluation of kidney biopsies. Clin Nephrol (1994) 1.06
Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop. Clin Nephrol (1985) 1.06
Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol (1990) 1.05
Morphology of ischemic acute renal failure, normal function, and cyclosporine toxicity in cyclosporine-treated renal allograft recipients. Kidney Int (1993) 1.01
One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.00
Cyclosporin and renal graft histology. J Clin Pathol (1986) 0.99
Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation (1994) 0.99
Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med (1994) 0.99
Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int (1995) 0.98
Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects. Transplantation (1995) 0.97
Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine. Arch Intern Med (1986) 0.97
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. Transplant Proc (1991) 0.94
FK 506-induced nephrotoxicity in rats. Transplant Proc (1991) 0.94
Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat. Am J Pathol (1989) 0.92
Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens (1995) 0.91
Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. Transplant Proc (1991) 0.90
Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant (1997) 0.90
Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest (1988) 0.90
Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation (1996) 0.90
Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. FEBS Lett (1985) 0.88
FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. Lab Invest (1995) 0.88
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation (1996) 0.86
Renal biopsy morphology in renal transplantation. A comparative study of the light-microscopic appearances of biopsies from patients treated with cyclosporin A or azathioprine prednisone and antilymphocyte globulin. Am J Surg Pathol (1984) 0.86
Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation (1996) 0.86
Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation (1988) 0.86
Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem (1996) 0.84
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol (1995) 0.84
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. Transplant Proc (1991) 0.83
FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). Transplant Proc (1991) 0.82
The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation (1996) 0.82
Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol (1994) 0.82
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. Transplant Proc (1993) 0.81
Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren Physiol Biochem (1995) 0.81
Role of reactive oxygen formation in the cyclosporin-A-mediated impairment of renal functions. Transplant Proc (1994) 0.80
Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. Transplant Proc (1991) 0.80
Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation (1990) 0.80
Efficacy of FK506 in renal transplantation. Ann N Y Acad Sci (1993) 0.80
FK506-associated thrombotic thrombocytopenic purpura. Transplantation (1993) 0.80
Myocyte vacuolization in infarct border zones is reversible. Am J Pathol (1985) 0.80
Disruption of renal function and gene expression by FK 506 and cyclosporine. Transplant Proc (1991) 0.79
Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol (1992) 0.79
Short-term FK 506-induced morphological changes in rat kidneys. Transplant Proc (1991) 0.79
The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl (1995) 0.79
Cyclosporine A and intravascular coagulation. Transplant Proc (1987) 0.79
Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol (1996) 0.79
Myocardial changes in cardiac transplant-associated coronary arteriosclerosis: potential for timely diagnosis. J Am Coll Cardiol (1992) 0.78
Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. Transplant Proc (1991) 0.78
Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. Transplant Proc (1991) 0.78
Ciclosporin-associated arteriolopathy: the renin producing vascular smooth muscle cells are more sensitive to ciclosporin toxicity. Clin Nephrol (1995) 0.77
Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci (1994) 0.77
Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats. Transplantation (1996) 0.77
Renal transplant morphology after long-term therapy with cyclosporine. Transplant Proc (1995) 0.77
Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine. Kidney Int (1985) 0.76
FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. Transpl Int (1994) 0.76
Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. Transplant Proc (1995) 0.76
Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. J Cardiovasc Pharmacol (1995) 0.76
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07
VENO-VENOUS BYPASS WITHOUT SYSTEMIC ANTICOAGULATION IN CANINE AND HUMAN LIVER TRANSPLANTATION. Surg Forum (1983) 2.30
THE USE OF COMBINED PRESERVATION TECHNIQUES FOR EXTENDED STORAGE OF ORTHOTOPIC LIVER HOMOGRAFTS. Surg Gynecol Obstet (1968) 2.20
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Complications of right lobe living donor liver transplantation. J Hepatol (2009) 1.73
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci U S A (2006) 1.46
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42
SUCCESSFUL ORTHOTOPIC TRANSPLANTATION OF LIVER HOMOGRAFTS AFTER EIGHT TO TWENTY-FIVE HOURS PRESERVATION. Surg Forum (1967) 1.37
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Origin of lymph node-derived lymphocytes in human hepatic allografts. Clin Transpl (1989) 1.24
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem (2001) 1.18
OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant (1991) 1.11
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther (2004) 1.11
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg (2005) 1.10
Augmenter of liver regeneration: an important intracellular survival factor for hepatocytes. J Hepatol (2008) 1.04
The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant (2005) 1.02
Humoral Antibodies in Patients After Renal Homotransplantation. Transplantation (1967) 0.96
Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant (2005) 0.95
Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status. Immunology (2013) 0.95
Functional characteristics of lymphocytes propagated from a human multivisceral allograft. Clin Transplant (1990) 0.94
Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation (2004) 0.91
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol (2002) 0.88
Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med (2008) 0.88
ALLOREACTIVE T LYMPHOCYTES CULTURED FROM LIVER TRANSPLANT BIOPSIES: ASSOCIATIONS OF HLA SPECIFICITY WITH CLINICOPATHOLOGICAL FINDINGS. Clin Transplant (1988) 0.87
The treatment of penetrating wounds of the inferior vena cava. Surgery (1962) 0.86
Cholera toxin-sensitive GTP-binding protein-coupled activation of augmenter of liver regeneration (ALR) receptor and its function in rat kupffer cells. J Cell Physiol (2010) 0.85
Smooth muscle tumor arising de novo in a liver allograft: A case report. Clin Transplant (1991) 0.82
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation (2006) 0.82
Simultaneous bone marrow and intestine transplantation promotes marrow-derived hematopoietic stem cell engraftment and chimerism. Blood (2006) 0.82
Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. Transplantation (2002) 0.81
Pancreatic transplantation at the University of Pittsburgh. Clin Transpl (2004) 0.81
Hepatic artery thrombosis following pediatric liver transplantation: Assessment of blood flow measurement in allografts. Clin Transplant (1989) 0.81
Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant (1992) 0.80
Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. Transplantation (2007) 0.78
Cadaveric renal transplantation using kidneys from donors greater than 60 years old. Clin Transplant (1992) 0.78
Kidney after nonrenal transplantation-the impact of alemtuzumab induction. Transplantation (2009) 0.78
Reversal of Graft-Versus-Host Disease with Infusion of Stored Autologous Bone Marrow Cells Following Combined Liver-Bone Marrow Allotransplantation in Man. Transplant Sci (1993) 0.78
Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol (2002) 0.78
Tolerance for organ recipients: a clash of paradigms. Liver Transpl (2006) 0.78
Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients. Pediatr Transplant (2006) 0.78
Induction of Pancreatic Islet Graft Acceptance: The Role of Antigen Presenting Cells. Transplant Sci (1992) 0.78
Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl (2008) 0.78
LIVER TRANSPLANTATION IN MAN. Ann N Y Acad Sci (1970) 0.78
The difficulty of eliminating donor leukocyte microchimerism in rat recipients bearing established organ allografts. Transplantation (2006) 0.78
Kidney/Bone Marrow Transplantation. Dial Transplant (1996) 0.76
The Problem of Frostbite in Civilian Medical Practice. Surg Clin North Am (1963) 0.75
LONG TERM RESULTS OF HEPATIC TRANSPLANTATION DURING THE CYCLOSPORINE ERA: THE PITTSBURGH EXPERIENCE. Transplant Clin Immunol (1987) 0.75
Transplantation. JAMA (1986) 0.75
World's longest surviving liver-pancreas recipient. Liver Transpl (2007) 0.75
Effect of homograft ischemia upon serum proteins after orthotopic liver transplantation. Surgery (1968) 0.75
Hepatic Regeneration. Viewp Dig Dis (1979) 0.75
On the crossroad between tolerance and posttransplant lymphoma. Curr Opin Organ Transplant (1997) 0.75
Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers. Xenotransplantation (1997) 0.75
Pancreatic complications following orthotopic liver transplantation. Clin Transplant (1992) 0.75
Prevention of Transplant Rejection: Can Tolerance be Achieved with Immunosuppressive Treatment? Clin Immunother (1996) 0.75
Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant (1993) 0.75
Liver Transplantation in the World: Present Conditions of Liver Transplantation from Cadaver Donors in USA. Kusuri No Chishiki (1995) 0.75
Blood Vessel Bank: Organization and Function. Bull Univ Miami Sch Med Jackson Meml Hosp (1957) 0.75
Successful salvage of mucormycosis infection of the forearm and osteomyelitis of the ulna. Hand (N Y) (2008) 0.75
Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction. Transplantation (2008) 0.75
Cold heparinized lactated Ringers with procaine (HeLP) preservation fluid in 266 living donor kidney transplantations. Transplantation (2007) 0.75
Causes of death after liver transplantation in children treated with cyclosporine and steroids. Clin Transplant (1989) 0.75
Long-term results of cyclosporine-steroid therapy in 131 non-matched cadaveric renal transplants. Clin Transplant (1987) 0.75
CRITICAL CARE MEDICINE AND LIVER TRANSPLANTATION. Crit Care (1985) 0.75
Fifty years later. Clin Transpl (2013) 0.75
Transplant innovation and ethical challenges: what have we learned? A collection of perspectives and panel discussion. Cleve Clin J Med (2008) 0.75
Recurrent liver disease after liver transplantation. Forum (Genova) (1997) 0.75